Hu Xie

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 10

Top Topics

Acute Lymphoblastic Leukemia

Peripheral Blood

Allogeneic Hematopoietic Stem Cell Transplantation

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Masumi Ueda Oshima, Hu Xie, Danniel Zamora, Mary E Flowers, Geoffrey R Hill, Marco Mielcarek, Brenda M Sandmaier, Theodore A Gooley, Michael J Boeckh
Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation. Blood advances (2023)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37 (2) (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37 (2) (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37 (2) (2022)
Yae Jean Kim, Alpana Waghmare, Hu Xie, Leona Holmberg, Mirta Maravilla Rosas, Keith R Jerome, Wendy M Leisenring, Chikara Ogimi, Angela P Campbell, Janet A Englund, Michael J Boeckh
Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes. Blood advances 6 (18) (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37 (2) (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37 (2) (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia 37 (2) (2022)
Carla S Walti, Anna B Halpern, Hu Xie, Erika S Kiem, E Lisa Chung, Kelda G Schonhoff, Emily M Huebner, Colleen Delaney, Catherine Liu, Steven A Pergam, Guang-Shing Cheng, Louise E Kimball, Wendy M Leisenring, Michael Boeckh, Roland Bruno Walter, Joshua A Hill
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia (2022)